Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 3,858 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 3,858 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $2.71, for a total transaction of $10,455.18. Following the sale, the insider owned 1,135,319 shares in the company, valued at approximately $3,076,714.49. This trade represents a 0.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Stock Up 3.0%

Shares of NSPR stock traded up $0.03 during mid-day trading on Thursday, reaching $1.03. 160,140 shares of the company’s stock traded hands, compared to its average volume of 182,457. InspireMD, Inc. has a 12 month low of $0.97 and a 12 month high of $2.93. The company has a market cap of $48.24 million, a P/E ratio of -1.37 and a beta of 0.82. The company’s 50-day moving average price is $1.40 and its 200-day moving average price is $1.68.

Institutional Trading of InspireMD

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in shares of InspireMD during the 1st quarter valued at about $29,000. XTX Topco Ltd bought a new position in shares of InspireMD in the 4th quarter worth approximately $30,000. Virtu Financial LLC bought a new position in shares of InspireMD in the 4th quarter worth approximately $31,000. Creative Planning bought a new position in shares of InspireMD in the 2nd quarter worth approximately $44,000. Finally, Legato Capital Management LLC bought a new position in shares of InspireMD in the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD News Summary

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NSPR shares. Maxim Group started coverage on shares of InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 target price on the stock. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Piper Sandler restated an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 price target on shares of InspireMD in a research note on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, InspireMD has an average rating of “Buy” and an average price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.